Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

[1]  G. Thomas,et al.  Breast cancer in the elderly , 2004 .

[2]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[3]  S. Loibl,et al.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.

[4]  S. Loibl,et al.  Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.

[5]  W. Eiermann,et al.  Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  D. Berry,et al.  Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Wildiers,et al.  International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Delozier,et al.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Loibl,et al.  Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[11]  M. Fukuoka,et al.  Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Rosner,et al.  Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Cohen,et al.  Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Cohen,et al.  Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. , 2005, JAMA.

[17]  G. Hortobagyi,et al.  Breast cancer treatment guidelines in older women. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Kiechle,et al.  P73 Phase III study evaluating the role of Docetaxel in theadjuvant therapy of breast cancer patients with extensive lymph node involvement (*4 LK+) — Current State of the ADEBAR Study , 2005 .

[19]  H. Cohen,et al.  Barriers to clinical trial participation by older women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Siu,et al.  Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Kiechle,et al.  Phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement (4 nodes+) — ADEBAR study , 2003 .

[22]  Xianglin L. Du,et al.  Discrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer , 2003, Annals of Internal Medicine.

[23]  E. Feuer,et al.  Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. , 2002, Journal of the National Cancer Institute.

[24]  R. Labianca,et al.  A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.

[25]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Cavalli,et al.  Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Goodman,et al.  A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer , 2000, Cancer investigation.

[28]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[29]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.